methoxy-morpholinyl-doxorubicin and Cardiomyopathies, Primary

methoxy-morpholinyl-doxorubicin has been researched along with Cardiomyopathies, Primary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agen, C; Bevilacqua, G; Danesi, R; Del Tacca, M; Grandi, M; Nardini, V	1

Other Studies

1 other study(ies) available for methoxy-morpholinyl-doxorubicin and Cardiomyopathies, Primary

Article	Year
3'-Deamino-3'-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:11 Topics: Animals; Cardiomyopathies; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Electrocardiography; Female; Heart; Humans; Rats; Rats, Wistar; Tumor Cells, Cultured; Tumor Stem Cell Assay	1993

Article

Year

3'-Deamino-3'-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity.

European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:11

Topics: Animals; Cardiomyopathies; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Electrocardiography; Female; Heart; Humans; Rats; Rats, Wistar; Tumor Cells, Cultured; Tumor Stem Cell Assay

1993